Clinical Management of Hyperkalemia

Rosano, 2018, Eur Heart J Cardiovasc Pharmacother, 4, 180, 10.1093/ehjcvp/pvy015 Rafique, 2017, Expert panel recommendations for the identification and management of hyperkalemia and role of patiromer in patients with chronic kidney disease and heart failure, J Manag Care Spec Pharm, 23, S10 Bandak, 2017, Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project, J Am Heart Assoc, 6, e005428, 10.1161/JAHA.116.005428 Howlett, 2016, The Canadian Cardiovascular Society heart failure companion: bridging guidelines to your practice, Can J Cardiol, 32, 296, 10.1016/j.cjca.2015.06.019 Kovesdy, 2017, Potassium homeostasis in health and disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension, Am J Kidney Dis, 70, 844, 10.1053/j.ajkd.2017.09.003 Bianchi, 2019, Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology, J Nephrol, 32, 499 Seferovic, 2019, Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management: an expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 21, 1169, 10.1002/ejhf.1531 Palmer, 2019, Physiology and pathophysiology of potassium homeostasis: core curriculum 2019, Am J Kidney Dis, 74, 682, 10.1053/j.ajkd.2019.03.427 Pochineni, 2018, Electrolyte and acid-base disorders in the renal transplant recipient, Front Med (Lausanne), 5, 261, 10.3389/fmed.2018.00261 Chaitman, 2016, Potassium-binding agents for the clinical management of hyperkalemia, P T, 41, 43 Lee Hamm, 2013, Acid-base and potassium homeostasis, Semin Nephrol, 33, 257, 10.1016/j.semnephrol.2013.04.006 Collins, 2017, Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes, Am J Nephrol, 46, 213, 10.1159/000479802 Gasparini, 2019, Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project, Nephrol Dial Transplant, 34, 1534, 10.1093/ndt/gfy249 Fleet, 2012, Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission, BMJ Open, 2, e002011, 10.1136/bmjopen-2012-002011 Conway, 2015, Serum potassium levels as an outcome determinant in acute medical admissions, Clin Med (Lond), 15, 239, 10.7861/clinmedicine.15-3-239 Einhorn, 2009, The frequency of hyperkalemia and its significance in chronic kidney disease, Arch Intern Med, 169, 1156, 10.1001/archinternmed.2009.132 Nakhoul, 2015, Serum potassium, end-stage renal disease and mortality in chronic kidney disease, Am J Nephrol, 41, 456, 10.1159/000437151 An, 2012, Severe hyperkalemia requiring hospitalization: predictors of mortality, Crit Care, 16, R225, 10.1186/cc11872 Korgaonkar, 2010, Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study, Clin J Am Soc Nephrol, 5, 762, 10.2215/CJN.05850809 Grodzinsky, 2016, Prevalence and prognosis of hyperkalemia in patients with acute myocardial infarction, Am J Med, 129, 858, 10.1016/j.amjmed.2016.03.008 Mathialahan, 2005, Enhanced large intestinal potassium permeability in end-stage renal disease, J Pathol, 206, 46, 10.1002/path.1750 Sterns, 1979, Disposition of intravenous potassium in anuric man: a kinetic analysis, Kidney Int, 15, 651, 10.1038/ki.1979.85 Alvestrand, 1984, Insulin-mediated potassium uptake is normal in uremic and healthy subjects, Am J Physiol, 246, E174 Berti, 2017, Sarcoplasmic reticulum Ca2+, Mg2+, K+, and Cl− concentrations adjust quickly as heart rate changes, J Mol Cell Cardiol, 103, 31, 10.1016/j.yjmcc.2016.10.018 Stillitano, 2008, Molecular basis of funny current (If) in normal and failing human heart, J Mol Cell Cardiol, 45, 289, 10.1016/j.yjmcc.2008.04.013 Wang, 2017, Ventricular action potential adaptation to regular exercise: role of β-adrenergic and KATP channel function, J Appl Physiol (1985), 123, 285, 10.1152/japplphysiol.00197.2017 Martin, 1947, Serum potassium, magnesium, and calcium levels in diabetic acidosis, J Clin Invest, 26, 217, 10.1172/JCI101799 Nilsson, 2017, Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system, Int J Cardiol, 245, 277, 10.1016/j.ijcard.2017.07.035 Chang, 2016, Antihypertensive medications and the prevalence of hyperkalemia in a large health system, Hypertension, 67, 1181, 10.1161/HYPERTENSIONAHA.116.07363 Krogager, 2015, Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction, Eur Heart J Cardiovasc Pharmacother, 1, 245, 10.1093/ehjcvp/pvv026 Krogager, 2017, Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data, Eur Heart J, 38, 104 Palmer, 2004, Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system, N Engl J Med, 351, 585, 10.1056/NEJMra035279 Palmer, 2018, Hyperkalemia across the continuum of kidney function, Clin J Am Soc Nephrol, 13, 155, 10.2215/CJN.09340817 Trevisan, 2018, Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists [published correction appears in Eur J Heart Fail. 2019;21(4):540], Eur J Heart Fail, 20, 1217, 10.1002/ejhf.1199 Adelborg, 2019, Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients – a population-based cohort study, PLoS One, 14, e0218739, 10.1371/journal.pone.0218739 Kim, 2017, Racial and ethnic differences in mortality associated with serum potassium in a large hemodialysis cohort, Am J Nephrol, 45, 509, 10.1159/000475997 2004, K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease, Am J Kidney Dis, 43, S1 Clase, 2020, Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disese: Improving Global Outcomes (KDIGO) Controversies Conference, Kidney Int, 97, 42, 10.1016/j.kint.2019.09.018 Palmer, 2016, Achieving the benefits of a high-potassium, paleolithic diet, without the toxicity, Mayo Clin Proc, 91, 496, 10.1016/j.mayocp.2016.01.012 Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151 Ponikowski, 2016, Eur J Heart Fail, 18, 891, 10.1002/ejhf.592 Yancy, 2017, J Am Coll Cardiol, 70, 776, 10.1016/j.jacc.2017.04.025 Montalescot, 2013, 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology [published correction appears in Eur Heart J. 2014;35(33):2260-2261], Eur Heart J, 34, 2949 2013, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease, Kidney Int Suppl, 3, 1 Rydén, 2014, Diab Vasc Dis Res, 11, 133, 10.1177/1479164114525548 2018, 9. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes–2018, Diabetes Care, 41, S86 Molnar, 2014, Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease, J Am Coll Cardiol, 63, 650, 10.1016/j.jacc.2013.10.050 Tai, 2017, Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials, BMC Cardiovasc Disord, 17, 257, 10.1186/s12872-017-0686-z Zannad, 2011, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, 364, 11, 10.1056/NEJMoa1009492 Xu, 2018, Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction: a meta-analysis of randomized controlled trials, Medicine (Baltimore), 97, e13690, 10.1097/MD.0000000000013690 Jafar, 2001, Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data [published correction appears in Ann Intern Med. 2002;137(4):299], Ann Intern Med, 135, 73, 10.7326/0003-4819-135-2-200107170-00007 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 Rassi, 2013, Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction, J Am Coll Cardiol, 61, 35, 10.1016/j.jacc.2012.08.1019 Epstein, 2015, Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors, Am J Manag Care, 21, S212 Savarese, 2018, Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry, Eur J Heart Fail, 20, 1326, 10.1002/ejhf.1182 De Nicola, 2018, Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice, J Nephrol, 31, 653 Tamargo, 2018, New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors, Cardiovasc Drugs Ther, 32, 99, 10.1007/s10557-017-6767-5 Beusekamp, 2018, Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF, Eur J Heart Fail, 20, 923, 10.1002/ejhf.1079 Rossignol, 2014, Circ Heart Fail, 7, 51, 10.1161/CIRCHEARTFAILURE.113.000792 Qiao, 2020, Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate, JAMA Intern Med, 180, 718, 10.1001/jamainternmed.2020.0193 Epstein, 2016, Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors, Am J Manag Care, 22, s311 Rossignol Butler, 2019, Novel potassium binders as enabling therapy in heart failure, Eur J Heart Fail, 21, 550, 10.1002/ejhf.1474 Aldahl, 2017, Associations of serum potassium levels with mortality in chronic heart failure patients, Eur Heart J, 38, 2890, 10.1093/eurheartj/ehx460 Ranjitkar, 2017, Establishing evidence-based thresholds and laboratory practices to reduce inappropriate treatment of pseudohyperkalemia, Clin Biochem, 50, 663, 10.1016/j.clinbiochem.2017.03.007 Don, 1990, Pseudohyperkalemia caused by fist clenching during phlebotomy, N Engl J Med, 322, 1290, 10.1056/NEJM199005033221806 Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019 Peacock, 2018, Real world evidence for treatment of hyperkalemia in the emergency department (REVEAL-ED): a multicenter, prospective, observational study, J Emerg Med, 55, 741, 10.1016/j.jemermed.2018.09.007 Galloway, 2019, Development and validation of a deep-learning model to screen for hyperkalemia from the electrocardiogram, JAMA Cardiol, 4, 428, 10.1001/jamacardio.2019.0640 Kovesdy, 2014, Management of hyperkalaemia in chronic kidney disease, Nat Rev Nephrol, 10, 653, 10.1038/nrneph.2014.168 Lindner Palmer, 2017, Diagnosis and treatment of hyperkalemia, Cleve Clin J Med, 84, 934, 10.3949/ccjm.84a.17056 2018 2018 2018 Beccari, 2017, Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [published correction appears in Core Evid. 2019;14:1], Core Evid, 12, 11, 10.2147/CE.S129555 Georgianos, 2018, Revisiting RAAS blockade in CKD with newer potassium-binding drugs, Kidney Int, 93, 325, 10.1016/j.kint.2017.08.038 Lepage, 2015, Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD, Clin J Am Soc Nephrol, 10, 2136, 10.2215/CJN.03640415 Rafique, 2020, Patiromer for treatment of hyperkalemia in the emergency department: a pilot study, Acad Emerg Med, 27, 54, 10.1111/acem.13868 Pitt, 2011, Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial, Eur Heart J, 32, 820, 10.1093/eurheartj/ehq502 Bakris, 2015, Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial [published correction appears in JAMA. 2015;314(7):731], JAMA, 314, 151, 10.1001/jama.2015.7446 Agarwal, 2019, Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial, Lancet, 394, 1540, 10.1016/S0140-6736(19)32135-X Weir, 2015, Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors, N Engl J Med, 372, 211, 10.1056/NEJMoa1410853 Peacock, 2020, Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase II, randomized, double-blind, placebo-controlled study (ENERGIZE), Acad Emerg Med, 27, 475, 10.1111/acem.13954 Packham, 2015, Sodium zirconium cyclosilicate in hyperkalemia, N Engl J Med, 372, 222, 10.1056/NEJMoa1411487 Kosiborod, 2014, Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial [published correction appears in JAMA. 2015;313(5):526], JAMA, 312, 2223, 10.1001/jama.2014.15688 Roger, 2019, Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE, Am J Nephrol, 50, 473, 10.1159/000504078 Zannad, 2020, Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study, ESC Heart Fail, 7, 54 Spinowitz, 2019, Sodium zirconium cyclosilicate in individuals with hyperkalemia: a 12-month phase 3 study, Clin J Am Soc Nephrol, 14, 798, 10.2215/CJN.12651018 Fishbane, 2019, A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia, J Am Soc Nephrol, 30, 1723, 10.1681/ASN.2019050450 Bounthavong, 2018, Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia [published correction appears in Pharmacoeconomics. 2019;37(8):1071], Pharmacoeconomics, 36, 1463, 10.1007/s40273-018-0709-3 Zann, 2017, Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate, Drug Des Devel Ther, 11, 2663, 10.2147/DDDT.S143461 Jadoul, 2014, Potassium-binding resins: associations with serum chemistries and interdialytic weight gain in hemodialysis patients, Am J Nephrol, 39, 252, 10.1159/000360094 Parks Laureati Noel, 2019, Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age, JAMA Intern Med, 179, 1025, 10.1001/jamainternmed.2019.0631 Harel, 2013, Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review, Am J Med, 126, 264.e9, 10.1016/j.amjmed.2012.08.016 Pitt, 2018, Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN, ESC Heart Fail, 5, 592, 10.1002/ehf2.12292 Kovesdy, 2018, Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients, Kidney Int Rep, 4, 301, 10.1016/j.ekir.2018.10.020 Epstein, 2016, Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer, Expert Opin Pharmacother, 17, 1435, 10.1080/14656566.2016.1190333 Bushinsky, 2015, Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia, Kidney Int, 88, 1427, 10.1038/ki.2015.270 Bhattarai, 2019, Patiromer acetate induced hypercalcemia: an unreported adverse effect, Case Rep Nephrol, 2019, 3507407 Wiederkehr, 2019, Case report: patiromer-induced hypercalcemia, Clin Nephrol Case Stud, 7, 51, 10.5414/CNCS109782 Kosiborod, 2015, Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia [letter], N Engl J Med, 372, 1577, 10.1056/NEJMc1500353 de Francisco, 2015, Normalization of serum bicarbonate with sodium zirconium cyclosilicate (ZS-9) in the phase 3 randomized, double-blind, placebo-controlled HARMONIZE study, Nephrol Dial Transplant, 30, 10.1093/ndt/gfv137.02 Stavros, 2014, Characterization of structure and function of ZS-9, a K+ selective ion trap, PLoS One, 9, e114686, 10.1371/journal.pone.0114686